Global Atopic Dermatitis Drugs Market 2017-2021 with LEO Pharma, Mylan, Valeant, Bayer HealthCare & Encore Dermatology Dominating - Research and Markets

DUBLIN--()--Research and Markets has announced the addition of the "Global Atopic Dermatitis Drugs Market 2017-2021" report to their offering.

The global atopic dermatitis drugs market to grow at a CAGR of 4.20% during the period 2017-2021.

Global Atopic Dermatitis Drugs Market 2017-2021, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the market landscape and its growth prospects over the coming years. The report also includes a discussion of the key vendors operating in this market. To calculate the market size, the report considers the revenue generated from the sales of atopic dermatitis drugs.

According to the report, atopic dermatitis is one of the most common forms of inflammatory skin diseases. Food allergy and severe atopic dermatitis coexist in approximately one-third of all children with atopic dermatitis. According to research studies, 5%-10% of all children have atopic dermatitis, and one-third of them have a food allergy. Globally, among babies aged three to 18 months with mild atopic dermatitis, 15% have certain food allergies. Research studies show that the early onset of severe atopic dermatitis in infancy is related to high risk of IgE food sensitization, which is commonly associated with food allergy.

Atopic dermatitis is affected by genetic and environmental factors. Biologic agents for moderate to severe atopic dermatitis provide control over the disease. The market currently lacks good and safe therapeutics, which increases the large unmet need. Biologics targeting adaptive immune responses have been tested in patients with atopic dermatitis who do not respond to other treatments.

Further, the report states that the FDA regulates the medicines used by the US public. Black box warnings are put in the labeling of prescription drugs or drug products, by the FDA, to warn users of serious hazards associated with the drug. This warning is issued when the FDA receives reports of adverse events related to drug usage after it has been approved.

Market Dynamics

Market drivers

  • Growing prevalence of food allergies exacerbating atopic dermatitis
  • Growing focus on systemic therapies
  • Increasing use of pharmacological products in developing countries

Market challenges

  • Black box warning for Elidel and Protopic
  • Highly genericized market
  • Poor patient adherence due to inadequate information on drug usage

Market trends

  • Increasing M&A leading to market consolidation
  • Launch of first biologic for atopic dermatitis
  • Growing focus on novel drugs

Key vendors

  • LEO Pharma
  • Mylan
  • Valeant
  • Bayer HealthCare
  • Encore Dermatology

Key Topics Covered:

Part 01: Executive summary

Part 02: Scope of the report

Part 03: Research Methodology

Part 04: Introduction

Part 05: An overview of atopic dermatitis

Part 06: Pipeline analysis

Part 07: Market landscape

Part 08: Five force analysis

Part 09: Market segment by ROA

Part 10: Geographical segmentation

Part 11: Market drivers

Part 12: Impact of drivers

Part 13: Market challenges

Part 14: Impact of drivers and challenges

Part 15: Market trends

Part 16: Vendor landscape

Part 17: Appendix

For more information about this report visit http://www.researchandmarkets.com/research/34t8mn/global_atopic

Contacts

Research and Markets
Laura Wood, Senior Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
Related Topics: Immune Disorders Drugs, Dermatological Drugs

Contacts

Research and Markets
Laura Wood, Senior Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
Related Topics: Immune Disorders Drugs, Dermatological Drugs